ProMIS Neurosciences Inc PMN

Positive Recent events

[retiredcop]

PMN is focusing on AD and ALS . New CEO suggested  these were two main identifed needs globally and PMN would in the running for potential treatments. These two announcements were a positive for PMN moving forward. as opposed to complicating things for us. 

https://www.alzforum.org/news/research-news/finally-big-win-all-outcomes-lecanemab-phase-3-topline-results
 
https://www.alzforum.org/news/community-news/fda-approves-als-drug-phase-2-data

[azzymaa]

Same ol crrap, sell this garbage and stop cheating people retiredcop

[M101]

The amylyx saga is good for us the way that aducanumab should have been, i.e. by staying clear of it. I hope it pans out for them and that our CEO makes commentary reflecting the scientific consensus that ALS more than most is a disease of multiple proteins, which is why it is not our lead despite Cashman's long focus on it.    

[G1945V]

RC is this from a quote made by the new CEO? "These two announcements were a positive for PMN moving forward. as opposed to complicating things for us." Is there more of an explanation for this? G1945V

[retiredcop]

NO.....

[M101]

I agree with RC's "instead of complicating" remark, which he would have put it in quotes had it been one. Complicating or compromising is all Gene and Elliot achieved with their adcanumab-wagon strategy. It was a tactic to delay and scape goat, blame the sector not the clown show. So I'm being sincere when I ask RC for some prediction about our new CEO's progressive

[Gbathat]

The lecanumab news is really great for PMN.   Significant results show benefit of the PMN310 mechanism. 12.5% ARIA-E with lecanumab justifies an alternative more specific approach- PMN310. Dosing high is key for successful treatment.  PMN310's selectivity will allow just that... GLTA longs